Interventional device developer Boston Scientific of Natick, MA, has released financial results for its 2004 fiscal third quarter (end-September 30).
For the period, the firm had net sales of $1.482 billion, up 69% compared with $876 million reported for the third quarter of 2003. Excluding the favorable impact of $32 million in foreign currency fluctuations, net sales were $1.45 billion, an increase of 66%, according to the firm.
Reported net income for the quarter, including net special charges of $146 million (after tax), rose to $258 million, compared with reported net income of $124 million for the same period last year. The net special charges include a $71 million addition to the firm's 401(k) retirement plan and a $75 million provision for legal and regulatory exposures, the company said.
By AuntMinnie.com staff writers
October 19, 2004
Related Reading
SonoSite, Boston Scientific team up, August 11, 2004
Boston Scientific recalls more stents, shares drop, August 6, 2004
Boston Scientific's Taxus stent back at Brigham, August 2, 2004
Boston Scientific gets FDA nod for Liberte clinical trial, July 22, 2004
FDA reviews Boston Scientific's stent recall - WSJ, July 21, 2004
Copyright © 2004 AuntMinnie.com
